Which has better earnings & valuation, CNTA or AVBP?

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Centessa Pharmaceuticals N/A N/A -$197.53M -$1.79 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is CNTA or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% ArriVent BioPharma N/A -48.98% -45.44%

Which has stronger earnings and valuation, AVBP or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is AVBP or BLTE more profitable?

Belite Bio's return on equity of -13.14% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% Belite Bio N/A -13.14% -12.88%

Does the media prefer AVBP or BLTE?

In the previous week, Belite Bio had 4 more articles in the media than ArriVent BioPharma. MarketBeat recorded 6 mentions for Belite Bio and 2 mentions for ArriVent BioPharma. Belite Bio's average media sentiment score of 0.80 beat ArriVent BioPharma's score of 0.00 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVBP or TWST?

In the previous week, Twist Bioscience had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 5 mentions for Twist Bioscience and 2 mentions for ArriVent BioPharma. Twist Bioscience's average media sentiment score of 1.21 beat ArriVent BioPharma's score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, AVBP or ERAS?

Erasca is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A Erasca N/A N/A -$124.55M -$0.93 N/A

Is AVBP or ERAS more profitable?

Erasca's return on equity of -35.31% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% Erasca N/A -35.31% -29.49%

Does the media prefer AVBP or ERAS?

In the previous week, Erasca had 35 more articles in the media than ArriVent BioPharma. MarketBeat recorded 37 mentions for Erasca and 2 mentions for ArriVent BioPharma. Erasca's average media sentiment score of 0.09 beat ArriVent BioPharma's score of 0.00 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 2 Very Positive mention(s) 1 Positive mention(s) 32 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to AMRX or AVBP?

In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than ArriVent BioPharma. MarketBeat recorded 9 mentions for Amneal Pharmaceuticals and 2 mentions for ArriVent BioPharma. Amneal Pharmaceuticals' average media sentiment score of 0.95 beat ArriVent BioPharma's score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ArriVent BioPharma (AVBP) Competitors

$31.54 +1.10 (+3.61%)

Closing price 04:00 PM Eastern

Extended Trading

$31.56 +0.02 (+0.05%)

As of 07:34 PM Eastern

Compare

AVBP vs. CNTA, BLTE, TWST, ERAS, and AMRX

Should you buy ArriVent BioPharma stock or one of its competitors? MarketBeat compares ArriVent BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ArriVent BioPharma include Centessa Pharmaceuticals (CNTA), Belite Bio (BLTE), Twist Bioscience (TWST), Erasca (ERAS), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does ArriVent BioPharma compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Centessa Pharmaceuticals presently has a consensus price target of $41.33, indicating a potential upside of 2.06%. ArriVent BioPharma has a consensus price target of $44.83, indicating a potential upside of 42.15%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, ArriVent BioPharma had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 2 mentions for ArriVent BioPharma and 0 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.00 equaled ArriVent BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
ArriVent BioPharma	Neutral

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

ArriVent BioPharma's return on equity of -48.98% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Summary

ArriVent BioPharma beats Centessa Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does ArriVent BioPharma compare to Belite Bio?

ArriVent BioPharma (NASDAQ:AVBP) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

ArriVent BioPharma has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

In the previous week, Belite Bio had 4 more articles in the media than ArriVent BioPharma. MarketBeat recorded 6 mentions for Belite Bio and 2 mentions for ArriVent BioPharma. Belite Bio's average media sentiment score of 0.80 beat ArriVent BioPharma's score of 0.00 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Belite Bio's return on equity of -13.14% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Belite Bio	N/A	-13.14%	-12.88%

ArriVent BioPharma currently has a consensus target price of $44.83, suggesting a potential upside of 42.15%. Belite Bio has a consensus target price of $203.00, suggesting a potential upside of 29.90%. Given ArriVent BioPharma's higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Belite Bio beats ArriVent BioPharma on 8 of the 12 factors compared between the two stocks.

How does ArriVent BioPharma compare to Twist Bioscience?

ArriVent BioPharma (NASDAQ:AVBP) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

ArriVent BioPharma has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, meaning that its stock price is 111% more volatile than the broader market.

9.5% of ArriVent BioPharma shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Twist Bioscience has higher revenue and earnings than ArriVent BioPharma. Twist Bioscience is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Twist Bioscience	$376.57M	15.29	-$77.67M	-$1.33	N/A

ArriVent BioPharma presently has a consensus price target of $44.83, suggesting a potential upside of 42.15%. Twist Bioscience has a consensus price target of $90.30, suggesting a potential downside of 2.32%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe ArriVent BioPharma is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Twist Bioscience had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 5 mentions for Twist Bioscience and 2 mentions for ArriVent BioPharma. Twist Bioscience's average media sentiment score of 1.21 beat ArriVent BioPharma's score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Summary

Twist Bioscience beats ArriVent BioPharma on 9 of the 16 factors compared between the two stocks.

How does ArriVent BioPharma compare to Erasca?

ArriVent BioPharma (NASDAQ:AVBP) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

ArriVent BioPharma has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, Erasca has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

ArriVent BioPharma currently has a consensus target price of $44.83, suggesting a potential upside of 42.15%. Erasca has a consensus target price of $21.64, suggesting a potential upside of 11.87%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, equities analysts plainly believe ArriVent BioPharma is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Erasca had 35 more articles in the media than ArriVent BioPharma. MarketBeat recorded 37 mentions for Erasca and 2 mentions for ArriVent BioPharma. Erasca's average media sentiment score of 0.09 beat ArriVent BioPharma's score of 0.00 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	32 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Erasca is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Erasca's return on equity of -35.31% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Erasca	N/A	-35.31%	-29.49%

Summary

Erasca beats ArriVent BioPharma on 9 of the 14 factors compared between the two stocks.

How does ArriVent BioPharma compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Amneal Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.90	$72.06M	$0.38	47.29
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Amneal Pharmaceuticals has a net margin of 4.01% compared to ArriVent BioPharma's net margin of 0.00%. ArriVent BioPharma's return on equity of -48.98% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Amneal Pharmaceuticals presently has a consensus price target of $16.60, indicating a potential downside of 7.62%. ArriVent BioPharma has a consensus price target of $44.83, indicating a potential upside of 42.15%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe ArriVent BioPharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Amneal Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than ArriVent BioPharma. MarketBeat recorded 9 mentions for Amneal Pharmaceuticals and 2 mentions for ArriVent BioPharma. Amneal Pharmaceuticals' average media sentiment score of 0.95 beat ArriVent BioPharma's score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amneal Pharmaceuticals beats ArriVent BioPharma on 10 of the 16 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.42B	$3.64B	$6.82B	$12.60B
Dividend Yield	N/A	2.19%	2.68%	9.52%
P/E Ratio	-9.09	11.33	22.09	21.54
Price / Sales	N/A	304.04	522.13	92.26
Price / Cash	N/A	156.74	50.43	59.93
Price / Book	4.24	8.01	10.18	6.10
Net Income	-$166.31M	$23.81M	$3.60B	$331.84M
7 Day Performance	-3.72%	-1.69%	-1.95%	-1.77%
1 Month Performance	-6.52%	-1.69%	-0.77%	-3.03%
1 Year Performance	44.08%	34.50%	19.01%	14.20%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.2087 of 5 stars	$31.54 +3.6%	$44.83 +42.1%	+41.2%	$1.42B	N/A	N/A	40
CNTA Centessa Pharmaceuticals	0.7433 of 5 stars	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200
BLTE Belite Bio	3.8618 of 5 stars	$146.68 -0.2%	$203.00 +38.4%	+163.3%	$5.89B	N/A	N/A	10	News Coverage Analyst Upgrade
TWST Twist Bioscience	1.9645 of 5 stars	$92.53 +2.4%	$87.30 -5.7%	+162.9%	$5.63B	$376.57M	N/A	990	Positive News
ERAS Erasca	1.631 of 5 stars	$19.50 +8.9%	$20.64 +5.8%	+1,061.3%	$5.57B	N/A	N/A	120	Trending News Analyst Forecast Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. CNTA, BLTE, TWST, ERAS, and AMRX

How does ArriVent BioPharma compare to Centessa Pharmaceuticals?

Summary

How does ArriVent BioPharma compare to Belite Bio?

Summary

How does ArriVent BioPharma compare to Twist Bioscience?

Summary

How does ArriVent BioPharma compare to Erasca?

Summary

How does ArriVent BioPharma compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. CNTA, BLTE, TWST, ERAS, and AMRX

How does ArriVent BioPharma compare to Centessa Pharmaceuticals?

Which has more volatility & risk, CNTA or AVBP?

Do institutionals and insiders believe in CNTA or AVBP?

Do analysts recommend CNTA or AVBP?

Does the media refer more to CNTA or AVBP?

Which has better earnings & valuation, CNTA or AVBP?

Is CNTA or AVBP more profitable?

Summary

How does ArriVent BioPharma compare to Belite Bio?

Which has more volatility & risk, AVBP or BLTE?

Does the media prefer AVBP or BLTE?

Which has stronger earnings and valuation, AVBP or BLTE?

Is AVBP or BLTE more profitable?

Do analysts prefer AVBP or BLTE?

Do insiders & institutionals hold more shares of AVBP or BLTE?

Summary

How does ArriVent BioPharma compare to Twist Bioscience?

Which has more risk and volatility, AVBP or TWST?

Do institutionals and insiders hold more shares of AVBP or TWST?

Which has better valuation and earnings, AVBP or TWST?

Do analysts prefer AVBP or TWST?

Does the media prefer AVBP or TWST?

Is AVBP or TWST more profitable?

Summary

How does ArriVent BioPharma compare to Erasca?

Which has more risk & volatility, AVBP or ERAS?

Do analysts rate AVBP or ERAS?

Do institutionals & insiders hold more shares of AVBP or ERAS?

Does the media prefer AVBP or ERAS?

Which has higher earnings & valuation, AVBP or ERAS?

Is AVBP or ERAS more profitable?

Summary

How does ArriVent BioPharma compare to Amneal Pharmaceuticals?

Which has better earnings and valuation, AMRX or AVBP?

Is AMRX or AVBP more profitable?

Do analysts rate AMRX or AVBP?

Which has more volatility & risk, AMRX or AVBP?

Do insiders & institutionals believe in AMRX or AVBP?

Does the media refer more to AMRX or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools